SEC Form 4 · accession 0001161697-26-000176

CATALYST PHARMACEUTICALS, INC. · CPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Legal Officer

Period of report

Jul 15, 2026

Accepted (ET)

Jul 17, 2026 · 4:15 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001369568

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, par value $0.001 per share	Jul 15, 2026	D	242,501	$31.50	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Options to purchase common stock^F5	$4.64	Jul 15, 2026	D	132,000	D	—	Dec 2, 2026	Common Stock	132,000	D
Options to purchase common stock^F5	$3.42	Jul 15, 2026	D	200,000	D	—	Dec 30, 2027	Common Stock	200,000	D
Options to purchase common stock^F5	$7.07	Jul 15, 2026	D	135,000	D	—	Dec 28, 2028	Common Stock	135,000	D
Options to purchase common stock^F5	$18.59	Jul 15, 2026	D	69,000	D	—	Dec 27, 2029	Common Stock	69,000	D
Options to purchase common stock^F6	$14.15	Jul 15, 2026	D	147,621	D	—	Dec 8, 2030	Common Stock	147,621	D
Options to purchase common stock^F6	$21.12	Jul 15, 2026	D	126,704	D	—	Nov 21, 2031	Common Stock	126,704	D
Options to purchase common stock^F6	$22.77	Jul 15, 2026	D	98,652	D	—	Nov 20, 2032	Common Stock	98,652	D
Restricted Stock Units^F2,F6	—	Jul 15, 2026	D	7,067	D	—	Dec 8, 2026	Common Stock	7,067	D
Restricted Stock Units^F2,F6	—	Jul 15, 2026	D	10,322	D	—	Nov 21, 2027	Common Stock	10,322	D
Restricted Stock Units^F2,F6	—	Jul 15, 2026	D	29,776	D	—	Nov 20, 2028	Common Stock	29,776	D

F1The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5Each Option was fully vested.
F6Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.